3.What type of clinical studies/research do you use Mass Cytometry for? More than one response can be selected.
4.Which area(s) in the CyTOF workflow do you struggle with? More than one response can be selected.
5a.Regarding experimental design, what are the main challenges you have encountered? More than one response can be selected.
5b. How have you attempted to solve these main challenges?
Your answer
6a.Regarding reagent availability, what are the main challenges you have encountered? More than one response can be selected
6b. How have you attempted to solve these main challenges?
Your answer
7a.Regarding protocol optimization, what are the main challenges you have encountered? More than one response can be selected.
7b. How have you attempted to solve these main challenges?
Your answer
8a.Regarding panel design and validation, what are the main challenges you have encountered? More than one response can be selected.
8b. How have you attempted to solve these main challenges?
Your answer
9a.Regarding sample processing, what are the main challenges you have encountered? More than one response can be selected.
9b How have you attempted to solve these main issues?
Your answer
10a.Regarding instrumentation, what are the main challenges you have encountered? More than one response can be selected.
10b. How have you attempted to solve these main challenges?
Your answer
11a. Regarding quality control, what are the main challenges you have encountered? More than one response can be selected.
11b. How have you attempted to solve these main challenges?
Your answer
12.Regarding software/data analysis and statistical evaluation, what are the main challenges you have encountered? More than one response can be selected.
12b. How have you attempted to solve these main challenges?
Your answer
13.Regarding industry regulation, what are the main challenges you have encountered? More than one response can be selected.
14.How do you typically account for batch effects with CyTOF data?
Clear selection
15.What platform do you use for CyTOF data analysis?
Clear selection
16.Do you think CyTOF is mature enough to be used in clinical trials?